Clinical calculator based on clinicopathological characteristics predicts local recurrence and overall survival following radical resection of stage II-III colorectal cancer

被引:0
|
作者
Huang, Fei [1 ]
Wei, Ran [2 ]
Mei, Shiwen [1 ]
Xiao, Tixian [1 ]
Zhao, Wei [1 ]
Zheng, Zhaoxu [1 ]
Liu, Qian [1 ]
机构
[1] Chinese Acad Med Sci & Peking Union Med Coll, Natl Clin Res Ctr Canc, Natl Canc Ctr, Dept Colorectal Surg,Canc Hosp, Beijing, Peoples R China
[2] Sun Yat Sen Univ, Affiliated Hosp 1, Dept Gastrointestinal Surg, Guangzhou, Guangdong, Peoples R China
来源
FRONTIERS IN ONCOLOGY | 2025年 / 15卷
关键词
colorectal cancer; nomogram; clinical risk factor; prognosis; local recurrence; COLON-CANCER; RECTAL-CANCER; CURATIVE RESECTION; ADJUVANT THERAPY; MANAGEMENT; SURGERY; FLUOROURACIL; PATTERNS; OUTCOMES;
D O I
10.3389/fonc.2025.1494255
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose This study aimed to analyze the risk factors and survival prognosis of local recurrence in stage II-III colorectal cancer (CRC) and develop a clinical risk calculator and nomograms to predict local recurrence and survival in treated patients.Methods Patients who underwent radical surgery between January 2009 and December 2019 at the China National Cancer Center were included. Multivariate nomograms and a clinical risk calculator based on Cox regression were developed. Discrimination was measured with an area under curve (AUC) and variability in individual predictions was assessed with calibration curves. We stratified patients into different risk groups according to the established model to predict their prognosis and guide clinical practice.Results The clinical risk calculator incorporated six variables: tumor thrombus, perineural invasion, tumor grade, pathology T-stage, pathology N-stage, and whether more than 12 lymph nodes were harvested. Our clinical risk calculator provided good discrimination, with AUC values of local recurrence-free survival (LRFS) (0.764) and overall survival (OS) (0.815) in the training cohort and LRFS (0.740) and OS (0.730) in the test cohort. Calibration plots illustrated excellent agreement between the clinical risk calculator predictions and actual observations for 3- and 5-year LRFS and OS. Recurrence risk-stratified analysis showed that low-risk patients were more likely to undergo salvage radical surgery when recurrent disease existed.Conclusion The clinical calculator can better account for tumor and patient heterogeneity, providing a more individualized outcome prognostication. The model is expected to aid in treatment planning, such as resectability evaluation, and it can be used in postoperative surveillance (https://oldcoloncancer.shinyapps.io/dynnomapp/).
引用
收藏
页数:12
相关论文
共 50 条
  • [1] Clinical Calculator Based on Molecular and Clinicopathologic Characteristics Predicts Recurrence Following Resection of Stage I-III Colon Cancer
    Weiser, Martin R.
    Hsu, Meier
    Bauer, Philip S.
    Chapman, William C.
    Gonzalez, Ivan A.
    Chatterjee, Deyali
    Lingam, Deepak
    Mutch, Matthew G.
    Keshinro, Ajaratu
    Shia, Jinru
    Vakiani, Efsevia
    Konishi, Tsuyoshi
    Shimada, Yoshifumi
    Stadler, Zsofia
    Segal, Neil H.
    Cercek, Andrea
    Saltz, Leonard
    Yaeger, Rona
    Varghese, Anna
    Widmar, Maria
    Wei, Iris H.
    Pappou, Emmanouil P.
    Smith, J. Joshua
    Nash, Garrett
    Paty, Philip
    Garcia-Aguilar, Julio
    Gonen, Mithat
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (08) : 911 - +
  • [2] Nomogram for predicting overall survival in stage II-III colorectal cancer
    Liu, Jungang
    Huang, Xiaoliang
    Yang, Wenkang
    Li, Chan
    Li, Zhengtian
    Zhang, Chuqiao
    Chen, Shaomei
    Wu, Guo
    Xie, Weishun
    Wei, Chunyin
    Tian, Chao
    Huang, Lingxu
    Jeen, Franco
    Mo, Xianwei
    Tang, Weizhong
    CANCER MEDICINE, 2020, 9 (07): : 2363 - 2371
  • [3] Cumulative Incidence, Risk Factors, and Overall Survival of Disease Recurrence after Curative Resection of Stage II-III Colorectal Cancer: A Population-based Study
    Boute, Tara C.
    Swartjes, Hidde
    Greuter, Marjolein J. E.
    Elferink, Marloes A. G.
    van Eekelen, Rik
    Vink, Geraldine R.
    de Wilt, Johannes H. W.
    Coupe, Veerle M. H.
    CANCER RESEARCH COMMUNICATIONS, 2024, 4 (02): : 607 - 616
  • [4] Tumor aggression-defense index-a novel indicator to predicts recurrence and survival in stage II-III colorectal cancer
    Wu, Tong
    Fang, Lin
    Ruan, Yuli
    Shi, Mengde
    Su, Dan
    Ma, Yue
    Ma, Ming
    Wang, Bojun
    Liao, Yuanyu
    Han, Shuling
    Lu, Xiaolin
    Zhang, Chunhui
    Liu, Chao
    Zhang, Yanqiao
    JOURNAL OF TRANSLATIONAL MEDICINE, 2025, 23 (01)
  • [5] Vitamin D Status and Survival in Stage II-III Colorectal Cancer
    Bao, Yichao
    Li, Yaqi
    Gong, Yan
    Huang, Qianxia
    Cai, Sanjun
    Peng, Junjie
    FRONTIERS IN ONCOLOGY, 2020, 10
  • [6] Pelvic local recurrence as first relapse predicts prognosis for clinical stage II/III lower rectal cancer: A clinicopathological investigation
    Uda, Shuji
    Mukai, Masaya
    Kishima, Kyoko
    Yokoyama, Daiki
    Hasegawa, Sayuri
    Koike, Takuya
    Tajima, Takayuki
    Nomura, Eiji
    Tomita, Kousuke
    Matsumoto, Tomohiro
    Hasebe, Terumitsu
    Makuuchi, Hiroyasu
    MOLECULAR AND CLINICAL ONCOLOGY, 2021, 14 (02) : 1 - 7
  • [7] Association of PTEN loss and local recurrence in stage II-III colon cancer
    Jiang, Z.
    Mehta, T. R.
    You, Y. N.
    Chang, G. J.
    Eng, C.
    Overman, M. J.
    Maru, D.
    Hamilton, S. R.
    Kopetz, S.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (04)
  • [8] Clinical determinants of survival in patients with stage II-III pancreatic cancer
    Itakura, Haruka
    Xu, Qinmei
    Toesca, Diego
    Vitzthum, Lucas
    Jamalian, Arash
    Schueler, Emil
    Alkim, Emel
    Baclay, J. Richelcyn
    Chang, Daniel Tandel
    Fisher Jr, George A.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (23_SUPPL) : 56 - 56
  • [9] The Ratio of CD86+/CD163+Macrophages Predicts Postoperative Recurrence in Stage II-III Colorectal Cancer
    Xu, Guozeng
    Jiang, Lei
    Ye, Cheng
    Qin, Guizhen
    Luo, Zhanxiong
    Mo, Yuzhen
    Chen, Jian
    FRONTIERS IN IMMUNOLOGY, 2021, 12
  • [10] Risk score based on ten lncRNA-mRNA expression predicts the survival of stage II-III colorectal carcinoma
    Diao, Ruigang
    Mu, Xiaodong
    Wang, Tingting
    Li, Shuqing
    PLOS ONE, 2017, 12 (08):